FDA Peptide Reclassification 2026: What It Means for Providers FDA mulls compounding for peptides previously flagged over safety risks BioSpace Important Update on FDA Changes Concerning Peptides Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of